The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Oct 2020
IL-6-based mortality risk model for hospitalized patients with COVID-19.
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. ⋯ This mortality risk model allows early risk stratification of hospitalized patients with COVID-19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to guide clinical decision making.
-
J. Allergy Clin. Immunol. · Oct 2020
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.
There is inconclusive and controversial evidence of the association between allergic diseases and the risk of adverse clinical outcomes of coronavirus disease 2019 (COVID-19). ⋯ In a Korean nationwide cohort, allergic rhinitis and asthma, especially nonallergic asthma, confers a greater risk of susceptibility to SARS-CoV-2 infection and severe clinical outcomes of COVID-19.